Immune Activation Is Associated With Neurocognitive Performance in Ugandan Adolescents Living With HIV.

Journal: Journal of acquired immune deficiency syndromes (1999)

Volume: 97

Issue: 3

Year of Publication: 2024

Affiliated Institutions:  Case Western Reserve University, Cleveland, OH. Joint Clinical Research Center, Kampala, Uganda. Makerere University, Kampala, Uganda. New York State Psychiatric Institute, New York, NY. The Ohio State University, Columbus, OH.

Abstract summary 

We examined relationships between neurocognition and immune activation in Ugandan adolescents with perinatally acquired HIV (PHIV). Eighty-nine adolescents in Kampala, Uganda (32 virally suppressed [<400 copies/mL] PHIV and 57 sociodemographically matched HIV-negative controls), completed a tablet-based neurocognitive test battery. Control-derived z-scores for 12 individual tests and a global/overall z-score were calculated. We measured plasma (soluble CD14 and CD163), monocyte (proportions of monocyte subsets), and T-cell (expression of CD38 and HLA-DR on CD4 + and CD8 + ) activation and gut markers. Spearman rank correlations and median regressions examined associations between test performance and immune activation. The median [IQR] age was 15 [13-16] years, and 40% were girls. The median time on antiretroviral therapy was 10 years [7-11] for PHIV; 87% had viral load <50 copies/mL. Compared with controls, global z-scores were lower among PHIV ( P = 0.05) and significantly worse on tests of executive functioning and delayed recall ( P 's ≤ 0.05). Overall, monocyte activation significantly correlated with worse test performance on global z-score (r = 0.21, P = 0.04), attention, processing speed, and motor speed (r = 0.2-0.3, P ≤ 0.01). T-cell activation was significantly correlated with worse performance on tests of learning, executive functioning, and working memory (r = 0.2-0.4, P ≤ 0.04). In PHIV, after adjusting for age, sex, and antiretroviral therapy duration, activated CD4 T cells remained associated with worse memory (β-0.3, 95% CI: -0.55 to -0.07, P = 0.01). PHIV with virologic suppression on antiretroviral therapy shows evidence of worse neurocognitive test performance compared with controls. Monocyte and T-cell activation is correlated with worse neurocognition in Ugandan youth with and without HIV, which has not been previously investigated in this setting.

Authors & Co-authors:  Dirajlal-Fargo Sahera S Sattar Abdus A Strah Monika M Karungi Christine C Gumikiriza-Onoria Joy Louise JL Santoro Anthony F AF Kirsch Courtney C Nanteza Angel A Ferraris Christopher M CM Tsapalas Daphne D Asiedu Nana N Funderburg Nicholas N Musiime Victor V McComsey Grace A GA Robbins Reuben N RN

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Patil G, Mbewe EG, Kabundula PP, Smith H, Mwanza-Kabaghe S, Buda A, et al. Longitudinal Cognitive Outcomes in Children With HIV in Zambia: 2-Year Outcomes From the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study. J Acquir Immune Defic Syndr 2022; 91(2):217–225.
Authors :  15
Identifiers
Doi : 10.1097/QAI.0000000000003483
SSN : 1944-7884
Study Population
Male,Female
Mesh Terms
Humans
Other Terms
Study Design
Study Approach
Country of Study
Uganda
Publication Country
United States